Research News
View articles by month and year
1–4 of 4 articles
-
T-DM1 (Kadcyla) Wins FDA Approval
Kadcyla, a targeted therapy medicine, has been approved by the U.S. Food and Drug Administration to treat HER2-positive metastatic breast cancer that has previously been treated with Herceptin and a taxane chemotherapy.
-
T-DM1 Granted Priority Review by FDA
The U.S. Food and Drug Administration has granted priority review to T-DM1 to treat HER2-positive, metastatic breast cancer.
-
T-DM1 Lengthens Survival in Women Diagnosed with HER2-Positive Advanced-Stage Disease
Women diagnosed with HER2-positive advanced-stage breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
-
T-DM1 Improves Survival in Women with HER2-Positive Metastatic Breast Cancer
Women diagnosed with HER2-positive metastatic breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
1–4 of 4 articles
